IMUX
Immunic, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.72
−0.31%Sep 2, 2026, 12:54 UTC
Immunic Inc announced it will host a virtual R&D day on September 9, 2026, focused on relapsing multiple sclerosis, ahead of expected topline results from its Phase 3 ENSURE trials by end of 2026.
Source:Aug 11, 2026, 10:30 UTC
Immunic, Inc. reported financial results for the second quarter ended June 30, 2026.